Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Despite Headwinds On Glivec, Novartis Gears Up To Bring Tasigna To India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - For many years Swiss pharmaceutical giant Novartis voiced reservations about certain provisions of the Indian patent laws and data exclusivity issues, but the maker of Glivec (imatinib) looks set to introduce its next-line therapy for chronic myeloid leukemia Tasigna (nilotinib) into the Indian market

You may also be interested in...

Tasigna Beats Sprycel To First-Line CML Punch

Now that Novartis' Tasigna (nilotinib) has been approved by FDA for the treatment of first-line chronic myeloid leukemia, the race has officially begun for two second-generation BCR-ABL kinase inhibitors to supplant the venerable market-leader, Novartis' Gleevec (imatinib)

Indian Pharmaceutical Alliance Defends Section 3(d) Of Patents Act, Says Statute Not Against Incremental Innovations

MUMBAI - The Indian Pharmaceutical Alliance - an influential lobbying group that represents 15 leading Indian drug makers - has stridently opposed a 2009 report published by the U.S.-India Business Council that called for certain changes in the country's Patents Act

Novartis Designs “Arogya Parivar” To Reach Real India In Its Rural Centers

MUMBAI - Swiss drug maker Novartis recently launched its ace anti-diabetes drug Galvus in India to take Merck's Januvia head on, but the company's larger focus seems to be shifting fast from the mega cities to the rural market where "real India lives.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts